Clinical Trial Update: ADI-PEG20, Obesity and Prediabetes [Phase 2]

View source ↗

Summary

A Phase 2 trial of ADI-PEG20 for obesity and prediabetes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Prediabetes

Drugs mentioned

• ADI-PEG20 (pegylated arginine deiminase)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Obesity, PreDiabetes | Phase 2 | Status: WITHDRAWN